Regulation of Clinical Trial Governance for Biotechnology in China

1. Introduction

China regulates biotechnology clinical trials through a comprehensive framework of pharmaceutical legislation, administrative regulations, ethical standards, data-protection laws, and judicial enforcement. The framework applies to biotechnology products such as recombinant proteins, monoclonal antibodies, vaccines, gene therapies, cell therapies, and other innovative biological medicines.

The principal objective is to ensure that biotechnology products are scientifically valid, clinically safe, ethically tested, and manufactured to appropriate quality standards before they are marketed. China’s regulatory approach combines centralized review by the National Medical Products Administration (NMPA), technical evaluation by the Center for Drug Evaluation (CDE), institutional ethics review, and continuing supervision of sponsors and clinical investigators.

An important feature of Chinese law is that clinical trial governance does not depend exclusively on drug approval legislation. It also involves informed consent, human genetic resources regulation, personal information protection, biosafety, and civil liability for harm caused during research.

2. Principal Legal and Regulatory Framework

A. Drug Administration Law

The Drug Administration Law of the People’s Republic of China, revised in 2019, provides the central statutory framework for drug research, clinical trials, registration, manufacturing, and marketing.

Under its clinical trial provisions, a drug clinical trial generally requires approval from the competent drug regulatory authority before commencement. The law establishes requirements for research quality, participant protection, and compliance with approved protocols.

Biotechnology sponsors must demonstrate that the investigational product has an adequate scientific basis and that its proposed clinical use can be evaluated through properly designed studies. The NMPA may impose regulatory consequences where a sponsor violates statutory requirements or submits unreliable research data.

The law also supports a system of drug registration and lifecycle supervision. Consequently, clinical trial compliance remains relevant even after a product receives marketing authorization.

B. Regulations on the Supervision and Administration of Drug Clinical Trials

China’s Regulations on the Supervision and Administration of Drug Clinical Trials and associated registration requirements establish operational controls over clinical research institutions, investigators, sponsors, and trial conduct.

The regulatory system requires appropriate institutional qualifications or filing status, scientific review, ethics committee oversight, and reliable documentation. Sponsors must ensure that trial activities follow the authorized protocol and applicable Good Clinical Practice (GCP) standards.

C. Good Clinical Practice

China’s revised Good Clinical Practice for Drug Trials, issued in 2020 and implemented from 2020, provides detailed standards governing the design, conduct, recording, and reporting of clinical trials.

GCP addresses:

Responsibilities of sponsors, investigators, and monitors.

Protection of participants’ rights, safety, and welfare.

Informed consent and ethics committee review.

Accurate source records and clinical data.

Adverse-event reporting and safety monitoring.

Quality assurance, inspections, and audit trails.

For biotechnology products, these requirements are especially significant because biological medicines may present immunogenicity, unexpected toxicity, complex manufacturing variability, or long-term risks that require extended follow-up.

3. Approval Procedure for Biotechnology Clinical Trials

The approval process generally involves the following stages.

Preclinical assessment: The sponsor submits relevant laboratory, pharmacological, toxicological, manufacturing, and quality data to support human testing.

NMPA clinical trial application: The sponsor submits the investigational product dossier. Under the Drug Administration Law, the statutory review period is generally 60 working days; if no decision is notified within that period, the application is deemed approved, subject to the applicable requirements.

National Medical Products Administration

Ethics committee approval: The relevant institutional ethics committee reviews the protocol, risks, consent documents, participant selection, and safeguards. Regulatory permission alone does not replace ethics approval.

Trial registration and commencement: The sponsor completes the applicable registration, institutional, contractual, and other pre-commencement requirements before enrolling participants.

Monitoring and reporting: Investigators and sponsors monitor safety, document adverse events, preserve reliable data, and report significant risks to the appropriate authorities.

Post-trial review: The resulting evidence supports further clinical development, marketing authorization, or discontinuation of the product.

4. Ethical Governance and Informed Consent

Ethical protection is a fundamental component of Chinese clinical trial governance. Article 20 of the Drug Administration Law requires an approved clinical trial protocol and ethics committee review. Article 21 requires truthful disclosure of the trial’s objectives and risks and voluntary informed consent. Article 22 requires sponsors to respond appropriately to newly identified safety concerns, including modifying, suspending, or terminating a trial where necessary.

National Medical Products Administration

Consent must be meaningful rather than merely formal. Participants should understand the investigational nature of the biotechnology product, foreseeable risks, alternative treatments, confidentiality arrangements, and their right to withdraw. Additional safeguards apply to vulnerable participants.

Biotechnology research may involve genetic samples, genomic sequencing, or heritable genetic interventions. The Personal Information Protection Law and human genetic resources rules may therefore apply alongside drug-trial requirements. International collaborative studies can require additional authorization or compliance measures for collecting, using, or providing Chinese human genetic resources to foreign parties.

5. Important Judicial Decisions and Legal Cases

A. He Jiankui Gene-Editing Case (2019)

The most significant Chinese criminal case concerning human genetic intervention is the He Jiankui case, decided by the Nanshan District People’s Court in Shenzhen in December 2019.

He Jiankui conducted experiments involving gene-edited human embryos that resulted in the birth of genetically edited children. The court found that the defendants had violated national regulations and medical ethics, used forged ethics review documents, and proceeded without establishing the safety and effectiveness of the intervention. He was sentenced to three years’ imprisonment and fined RMB 3 million. Two collaborators also received criminal sentences.

Supreme People's Court

Legal significance: The case demonstrates that scientific innovation does not exempt researchers from ethics review, professional qualification requirements, or medical regulation. It also illustrates that serious misconduct in human biotechnology can attract criminal liability, rather than merely administrative sanctions.

The case concerned reproductive gene editing and illegal medical practice, not an ordinary NMPA-authorized drug trial. Nevertheless, it is an important precedent for the limits of ethically unacceptable human biotechnology experimentation.

B. Legislative Consequences of the He Jiankui Case

The controversy contributed to stronger statutory safeguards. Article 1009 of China’s Civil Code, effective in 2021, addresses medical and scientific research activities involving human genes and human embryos, requiring compliance with relevant laws, administrative regulations, and ethical standards. Criminal Law Amendment XI also introduced an offence concerning illegal human embryo gene editing and cloning.

These developments strengthened the legal basis for controlling research that creates serious risks to human dignity, health, and public interests.

PMC

6. New Biomedical Technology Regulation in 2026

China’s regulatory framework has developed further through the Regulation on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies, State Council Order No. 818, effective 1 May 2026.

This regulation establishes a separate governance framework for qualifying new biomedical technologies, including clinical research and translational application. It is particularly relevant to cell therapies, gene-editing technologies, and other innovations that may fall outside the conventional drug or medical-device pathway. The applicable classification determines which regulatory route must be followed.

ScienceDirect

In addition, China’s revised Good Clinical Practice, NMPA No. 50 of 2026, took effect on 1 September 2026, replacing the 2020 version and incorporating principles from ICH E6(R3). Accordingly, the 2020 GCP framework should not be treated as the current governing version for trials conducted after that date.

ClinRegs

7. Liability and Enforcement

Non-compliance can result in suspension or termination of trials, regulatory penalties, restrictions on research activities, and potential criminal prosecution. Sponsors may also face civil liability where unlawful conduct causes injury to participants.

Liability depends on the facts, including whether the sponsor or investigator breached a legal duty, whether informed consent was properly obtained, whether adverse events were handled appropriately, and whether the breach caused the injury. Contractual arrangements with contract research organisations do not automatically eliminate a sponsor’s regulatory responsibilities.

8. Conclusion

China’s biotechnology clinical trial governance system combines drug registration, institutional ethics review, informed consent, scientific quality controls, genetic-resource governance, and judicial enforcement. The He Jiankui case demonstrates the serious consequences of bypassing ethical and regulatory safeguards, while the 2026 reforms show that China is developing distinct pathways for emerging biomedical technologies.

For biotechnology developers, the essential legal requirement is to identify the correct regulatory classification before commencing human research, obtain the necessary regulatory and ethics approvals, protect participants throughout the study, and maintain verifiable safety and research records.